The present disclosure provides an active material comprising a mixed metal oxide in a hydrotalcite derived rocksalt structure, a processes to convert paraffins to corresponding olefins and or heavier hydrocarbons using the active material, and a method of preparing the active material.

The present disclosure provides an active material comprising a mixed metal oxide in a hydrotalcite derived rocksalt structure, a processes to convert paraffins to corresponding olefins and or heavier hydrocarbons using the active material, and a method of preparing the active material.

The present invention relates to a catalyst for oxidative dehydrogenation of butene and a method for producing the same. The catalyst for oxidative dehydrogenation of butene has a large amount of Mo—Bi phase acting as a reaction active phase on the surface, and therefore, can exhibit high catalytic activity, high conversion rate and high butadiene selectivity in the oxidative dehydrogenation of butene.

The present invention relates to a catalyst for oxidative dehydrogenation of butene and a method for producing the same. The catalyst for oxidative dehydrogenation of butene has a large amount of Mo—Bi phase acting as a reaction active phase on the surface, and therefore, can exhibit high catalytic activity, high conversion rate and high butadiene selectivity in the oxidative dehydrogenation of butene.

The invention relates to a shaped catalyst body in the form of a tetralobe having four circular through-passages, with the midpoints of the through-passages forming a square and the spacings between in each case two adjacent through-passages being from 0.8 to 1.2 times the thickness of the outer walls of the through-passages. The shaped catalyst body is used for the oxidation of S02 to S03.

The invention relates to a shaped catalyst body in the form of a tetralobe having four circular through-passages, with the midpoints of the through-passages forming a square and the spacings between in each case two adjacent through-passages being from 0.8 to 1.2 times the thickness of the outer walls of the through-passages. The shaped catalyst body is used for the oxidation of S02 to S03.

The present invention relates, at least in part, to a process for making chlorotrifluoroethylene (CFO-1113) from 1,2-dichloro-1,1,2-trifluoroethane (HCFC-123a). In certain aspects, the process includes dehydrochlorinating 1,2-dichloro-1,1,2-trifluoroethane (HCFC-123a) in the presence of a catalyst selected from the group consisting of (i) one or more metal halides; (ii) one or more halogenated metal oxides; (iii) one or more zero-valent metals or metal alloys; (iv) combinations thereof.

A catalytic composition useful for the conversion of an olefin selected from the group consisting of propylene, isobutylene or mixtures thereof, to acrylonitrile, methacrylonitrile, and mixtures thereof. The catalytic composition comprises a complex of metal oxides comprising rubidium, bismuth, cerium, molybdenum, iron and other promoters, with a desirable composition.

Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.

Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.